Y90 Radioembolization for Locally Advanced HCC

UCLA Health

S. Padia

HCC Percutaneous Radio-Ablation Using BAT-90: Results of an Ongoing …

Malkhaz Mizandari

SIR 2024 Insights: Route90 US IDE Pivotal Study Early Results in Rad…

SIR 2024 Insights

A. Kennedy

Colorectal Liver Metastases: Liver-Directed Therapies - Embolization…

Penn Medicine Abramson Cancer Center

M. Soulen

New and Evolving Clinical Trials: Embolotherapy

SIR 2022 Coverage

M. Soulen

Dosing Radioembolization for HCC: Why Dose Calculation Is the Most I…

Shamar Young

LEGACY: A Multicenter Study Confirming TheraSphere™ as a Neoadjuvant…

Boston Scientific

V. Bishay

Liver Directed Therapy in 2021: What Are the Advances in Transarteri…

UCLA Health

S. Padia

TheraSphere™ Y-90 Glass Microspheres: The DOSISPHERE-01 Trial

Boston Scientific

Liver-Directed Therapy for mCRC: What Is the Goal, When to Use and H…

Memorial Sloan Kettering Cancer Center

A. Cercek

Stage C HCC Clinical Data Review: Resin Radioembolization and Kinase…

Cedars Sinai

J. Marrero, W. C. Maddrey

TheraSphere™ Y-90 Glass Microspheres: The LEGACY Study

Boston Scientific

2L Yttrium-90 Radioembolization With Chemo for CRC Liver Metastases

ecancer

M. Mulcahy

Embolization Optimization with Proximal Protection: Principles and P…

Theresa Caridi

Practical Approach to Y90 Dosimetry: Using the DAVYR App

Ripal Gandhi

Principles of Y90 Dosimetry

Ripal Gandhi

Liver Case Review: 9.5 cm Liver Mass- HCC

Symposium on Clinical Interventional Oncology (CIO 2018)

Top Three Clinical Studies in Y90

Nicholas Fidelman

Macroaggregated Albumin (MAA) Prior to Planned SIRT Y90 Segmentectomy

TREAT Symposium

E. Kim

MAA Mapping for SIRTEX Y90 Lobectomy: High CFA Access Risk

TREAT Symposium

A. Fischman